Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterNo recent work listed

Paul S. Ritch

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5057163122. Sources: ClinicalTrials.gov.

Their work

Papers
27 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
68
Papers, trials and grants by year

2011: 1 trial · 2012: none · 2013: 1 paper · 2014: 4 papers · 2015: 5 papers · 2016: 4 papers · 2017: 3 papers · 2018: 2 papers · 2019: 2 papers · 2020: 6 papers

Papers 27

  1. Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? Co-author DOI 10.1007/s11605-019-04423-6↗
  2. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. Co-author DOI 10.1016/j.hpb.2020.03.022↗
  3. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cance… Co-author DOI 10.1016/j.surg.2020.04.031↗
  4. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003049↗
  5. Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00460↗
  6. Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Co-author DOI 10.3389/fonc.2020.00500↗
  7. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1002/cam4.2425↗
  8. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Co-author DOI 10.1016/j.surg.2019.05.010↗
  9. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002957↗
  10. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancrea… Co-author DOI 10.1200/jco.2017.74.9564↗
  11. Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer. Co-author DOI 10.1007/s11605-016-3319-4↗
  12. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? Co-author DOI 10.1007/s11605-017-3544-5↗
  13. Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer? Co-author DOI 10.1016/j.prro.2017.06.013↗
  14. Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated? Co-author DOI 10.1002/jso.24361↗
  15. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Co-author DOI 10.1016/j.surg.2015.09.018↗
  16. Evolution of the Management of Resectable Pancreatic Cancer. Co-author DOI 10.1200/jop.2016.015818↗
  17. Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. Co-author DOI 10.1200/jop.2016.016162↗
  18. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Co-author DOI 10.1016/j.surg.2015.06.017↗
  19. Neoadjuvant therapy for localized pancreatic cancer: support is growing? First author DOI 10.1097/sla.0000000000000996↗
  20. Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. Co-author DOI 10.1111/hpb.12325↗
  21. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. Co-author DOI 10.1111/hpb.12448↗
  22. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. Co-author DOI 10.3978/j.issn.2078-6891.2015.053↗
  23. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Co-author DOI 10.1007/s00280-014-2499-4↗
  24. Patency rates of portal vein/superior mesenteric vein reconstruction after pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s11605-014-2635-9↗
  25. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2014.09.010↗
  26. Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility? Co-author DOI 10.1111/hpb.12074↗
  27. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic canc… Co-author DOI 10.1093/annonc/mdt066↗

Trials 1

  1. Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") Principal investigator NCT01726582↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Douglas B. Evans · 23 shared papers, 2014–2020 · strength 1.59
  2. Susan Tsai · 22 shared papers, 1 shared trial, 2011–2020 · strength 1.56
  3. Bradley A. Erickson · 22 shared papers, 2014–2020 · strength 1.54
  4. Kathleen K. Christians · 21 shared papers, 1 shared trial, 2011–2020 · strength 1.49
  5. Ben George · 19 shared papers, 2014–2020 · strength 1.33
  6. William Adrian Hall · 10 shared papers, 2017–2020 · strength 0.87
  7. Mohammed Aldakkak · 9 shared papers, 2015–2020 · strength 0.71
  8. Ashley N. Krepline · 9 shared papers, 2014–2020 · strength 0.62
  9. Parag P. Tolat · 8 shared papers, 2014–2020 · strength 0.53
  10. Callisia Nathelee Clarke · 6 shared papers, 2017–2020 · strength 0.53
  11. Chad A. Barnes · 6 shared papers, 2017–2020 · strength 0.53
  12. Kulwinder S. Dua · 5 shared papers, 2016–2020 · strength 0.42
  13. Fabian Mc. Johnston · 5 shared papers, 2014–2016 · strength 0.24
  14. Naveen M. Kulkarni · 2 shared papers, 2020 · strength 0.19
  15. D. Wittmann · 2 shared papers, 2020 · strength 0.19
  16. Catherine E. Hagen · 2 shared papers, 2019–2020 · strength 0.18
  17. Andrea J. Bullock · 2 shared papers, 2018–2019 · strength 0.13
  18. Andrea Wang‐Gillam · 2 shared papers, 2018–2019 · strength 0.13
  19. Kiran Kalyan Turaga · 3 shared papers, 2014–2015 · strength 0.12
  20. Lindsay A. Bliss · 1 shared paper, 2020 · strength 0.11
  21. Mandana Kamgar · 1 shared paper, 2020 · strength 0.10
  22. Eileen Mary O'Reilly · 2 shared papers, 2013–2019 · strength 0.10
  23. Neil R. Jariwalla · 1 shared paper, 2020 · strength 0.09
  24. Sam G. Pappas · 2 shared papers, 2014–2015 · strength 0.08
  25. Alexander Craig Mackinnon · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.